Assessing the Actionability of KRAS Mutations in NSCLC
June 23rd 2020
KRAS mutations are found in approximately in 25% of all NSCLC, and it was not until recently that the previously coined “undruggable target” showed signals of actionability with KRAS mutation–specific therapy, tumor-suppressor–specific therapy, and anti-inflammatory therapy.